CenTrial GmbH Report issue

For profit Phase 2 Phase 3
Founded: Tubingen Germany (2001)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2007
NCT00656422
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Keratosis (Phase 2)

Keratosis, Actinic (Phase 2)

Weight Gain (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5